The long-term efficacy and safety of canagliflozin , a sodium glucose co-transporter @ inhibitor , was evaluated over @weeks in patients aged @-@years with type @ diabetes mellitus ( T@DM ) inadequately controlled on a stable antihyperglycaemic agent regimen .